Clinical trials: Cancer, Bladder
Bladder Cancer
Comparative Study of Hexvix Blue Light Cystoscopy and White Light Cystoscopy in the Detection of Bladder Cancer
A study to compare Hexvix Blue light cstoscopy with standard White light cystoscopy in the detection of bladder cancer.
- Trial name
- NCT05600322
- Testing
- Hexaminolevulinate Hydrochloride, Richard Wolf Photodynamic Diagnostic Equipment (PDD) system
- Where
- 7 sites in China
- Volunteers
- 158 people
- Sponsor
- Photocure
Urinary Bladder Neoplasms, Colorectal Cancer
A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours
A Phase I/IIa First-in-human, Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD8853 in Participants with Selected Advanced/Metastatic Solid Tumours.
- Conditions
- Urinary Bladder Neoplasms, Colorectal Cancer, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT05397171
- Testing
- AZD8853, Zirconium-89 crefmirlimab berdoxam
- Where
- 6 sites in United States, Canada
- Volunteers
- 17 people
- Sponsor
- AstraZeneca
Urothelial Carcinoma
Study of Avelumab and Tuvusertib in Participants With Advanced Urothelial Cancer That Has Progressed on Prior Anti-PD-(L)1 Therapy (JAVELIN DDRiver Bladder)
The purpose of this study is to assess the antitumor activity of avelumab in combination with tuvusertib in terms of objective response in participants with advanced urothelial carcinoma.
- Trial name
- NCT06424717
- Testing
- Avelumab, Tuvusertib
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Non Muscle Invasive Bladder Cancer
Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin
To evaluate the activity of intravesical administration of CG0070 and intravenous administration of Pembrolizumab in patients with tissue pathology-confirmed non-muscle invasive bladder cancer (NMIBC) who have…
- Trial name
- CORE-001 (NCT04387461)
- Testing
- CG0070, Pembrolizumab Injection, n-dodecyl-B-D-maltoside
- Where
- 19 sites in United States, South Korea
- Volunteers
- 35 people
- Sponsor
- CG Oncology, Inc.
Muscle Invasive Bladder Cancer
Clinical Performance Evaluation of the C2i Test
The overall objective of this study is to demonstrate the safety and effectiveness by means of investigation of the ability of C2i-Test to predict 2-year recurrence-free survival post-RC in stage II-IIIA MIBC patients.
- Trial name
- NCT05860543
- Testing
- C2i-WGS-MRD Test
- Sponsor
- University of Texas Southwestern Medical Center
Advanced Solid Tumor, Colorectal Cancer
A Study of KF-0210 in Advanced Solid Tumors Patients
The purpose of this Phase I, Multi-Center, Open-Label Study is to evaluate the safety, tolerability, Pharmacokinetics, Pharmacodynamics and anti-tumor activity of KF-0210 in participants with advanced solid tumors.
- Conditions
- Advanced Solid Tumor, Colorectal Cancer, Lung Cancer, Squamous Cell Carcinoma of the Esophagus
- Trial name
- NCT04713891
- Testing
- KF-0210 tablets, 120 mg, KF-0210 tablets, 240 mg, KF-0210 tablets, 450 mg
- Where
- Australia
- Volunteers
- 14 people
- Sponsor
- Keythera Pharmaceuticals (Australia) Pty Ltd
Bladder (Urothelial, Transitional Cell) Cancer, MRI
Bp-MRI Based Multi-planar VI-RADS
This study is a prospective, single-center, observational clinical trial, enrolling 100 patients with malignant bladder tumors admitted to the Department of Urology at the People's Hospital of Jiangsu Province for treatment with…
- Trial name
- NCT06607250
- Testing
- MRI
- Where
- China
- Volunteers
- 95 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Bladder Cancer
Radiation Therapy and Chemotherapy in Treating Patients With Stage I Bladder Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal…
- Trial name
- NCT00981656
- Testing
- cisplatin, 5-fluorouracil, Mitomycin
- Where
- 13 sites in United States
- Volunteers
- 37 people
- Sponsor
- Radiation Therapy Oncology Group
Bladder Cancer
S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer
The primary focus of this study is to see if looking at tumor biomarkers using a program called coexpression extrapolation or "COXEN" may predict a patient's response to chemotherapy before surgery.
- Trial name
- COXEN (NCT02177695)
- Testing
- Gemcitabine, Cisplatin, Methotrexate
- Where
- 566 sites in United States
- Volunteers
- 237 people
- Sponsor
- SWOG Cancer Research Network
Bladder Cancer
Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
Patients with muscle-invasive bladder cancer (MIBC) who can not receive cisplatin or refuse cisplatin therapy will receive nivolumab or nivolumab/lirilumab before a planned surgical procedure called a radical cystectomy (RC) to…
- Trial name
- PrE0807 (NCT03532451)
- Testing
- Nivolumab, Nivolumab/Lirilumab
- Where
- 8 sites in United States
- Volunteers
- 43 people
- Sponsor
- PrECOG, LLC.
Bladder Cancer
Bladder Cancer and ExeRcise Training During IntraVesical ThErapy
Bladder cancer is the fifth most common cancer in Canada and has the eighth highest cancer mortality rate. The treatment for the most frequent type of bladder cancer is surgically removing the tumour followed by six weeks of…
- Trial name
- BRAVE (NCT04593862)
- Testing
- High-Intensity Interval Training
- Where
- Canada
- Volunteers
- 25 people
- Sponsor
- University of Alberta
Bladder Cancer, Urothelial Carcinoma
Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)
This study aims to demonstrate that home instillation of UGN-102 is a feasible alternative to instillation in a clinical setting, which might mitigate patient challenges (logistical, expense, and comfort) when receiving treatment…
- Conditions
- Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
- Trial name
- NCT05136898
- Testing
- UGN-102
- Where
- 5 sites in United States
- Volunteers
- 8 people
- Sponsor
- UroGen Pharma Ltd.
Bladder Cancer, Infections
Infectious Complications After Cystectomy: A Prospective Observational Study
Patients undergoing cystectomy for either oncological or non-oncological indications are prospectively enrolled following informed consent.
- Conditions
- Bladder Cancer, Infections, Infection, Bacterial, Infection, Hospital
- Trial name
- NCT05153694
- Testing
- Cystectomy
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Colorectal Cancer, Bladder Cancer
Connecting Audio and Radio Sensing Systems to Improve Care at Home
This study aims to assess the usability of the innovative Audio + Radio (AURA) system in enhancing personalized supportive care for cancer patients and caregivers during the post-ostomy care transition by collecting information…
- Conditions
- Colorectal Cancer, Bladder Cancer, Ovarian Cancer, Cervical Cancer
- Trial name
- AURA (NCT05344950)
- Testing
- Audio + Radio (AURA)
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Advanced Breast Cancer, Treatment-Refractory Solid Tumors
TAS-116 Plus Palbociclib in Breast and Rb-null Cancer
The purpose of this study is to evaluate the safety and efficacy of TAS-116 with palbociclib in two groups of patients: Patients with advanced breast cancer that has become worse after taking palbociclib alone Patients with…
- Conditions
- Advanced Breast Cancer, Treatment-Refractory Solid Tumors, Retinoblastoma Deficiency, SCLC
- Trial name
- NCT05655598
- Testing
- Palbociclib Oral Product, TAS-116
- Where
- United States
- Sponsor
- Brown University
Bladder Cancer, Urinary Bladder Neoplasms
Trimodality Treatment in Bladder Cancer
Bladder cancer is a malignant disease that affects a large number of people worldwide. An increase in the incidence of this type of cancer has been observed in recent decades, leading to a growing interest in understanding its…
- Conditions
- Bladder Cancer, Urinary Bladder Neoplasms, Bladder Disease
- Trial name
- NCT06395701
- Testing
- radioteraphy and chemotherapy after RTU --trimodality therapy--
- Where
- Spain
- Volunteers
- 200 people
- Sponsor
- Consorci Sanitari de Terrassa
NMIBC
SHR-1501 Combined With SHR-2005 for High-Risk Non-Muscle Invasive Bladder Cancer Which is Not Completely Resectable by TURBt
This is a single-center, single-arm, phase Ib/II study, aimed at assessing the safety and efficacy of SHR-1501 in combination with SHR-2005 as treatment for patients with high-risk non-muscle invasive bladder cancer (HR NMIBC)…
- Trial name
- NCT06588179
- Testing
- SHR-1501+SHR-2005
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Fudan University
Bladder Carcinoma
Evaluating Sexual Function in Women Undergoing a Radical Cystectomy for Bladder Cancer
This study evaluates the general physical, emotional, and sexual function in women undergoing a radical cystectomy for bladder cancer.
- Trial name
- NCT05399004
- Testing
- Survey Administration
- Where
- 14 sites in United States
- Volunteers
- 34 people
- Sponsor
- Mayo Clinic
Bladder Cancer
MK-3475/BCG in High Risk Superficial Bladder Cancer
This is a single center Phase I safety and efficacy study of MK-3475 therapy used in combination with bladder infused BCG treatment for patients, 18 years or older, with high risk superficial bladder cancer (cancer not yet…
- Trial name
- MARC (NCT02324582)
- Testing
- Intravenous MK-3475/ Intravesical BCG
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Southern Illinois University
Anemia, Carcinoma, Non-Small-Cell Lung
To Determine Safe and Effective Dose of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Participants With Advanced Non-small Cell Lung Cancer
The purpose of this study was to determine an effective and safe dose of sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia (CIA) in participants with metastatic non-small cell lung cancer (NSCLC) who are…
- Conditions
- Anemia, Carcinoma, Non-Small-Cell Lung, Carcinoma, Small-Cell Lung, Bladder Cancer
- Trial name
- NCT01284348
- Testing
- Sotatercept 15 mg, Sotatercept 30 mg
- Volunteers
- 26 people
- Sponsor
- Merck Sharp & Dohme LLC